Humira deal with Amgen is a clear vindication of AbbVie’s patent strategy
AbbVie recently settled its dispute with Amgen, whose Amjevita biosimilar it accused of infringing its patents for Humira, the world’s best-selling drug. Though clearing an eventual path to market for Amgen’s drug, the deal constitutes a major…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.